Analyst firms · J.P. Morgan · PCRX

J.P. Morgan PCRX price target and rating history

Pacira BioSciences Inc. (PCRX) · Health Care

J.P. Morgan rates Pacira BioSciences Inc. (PCRX) Underweight with a $10 price target, as of its latest action on Aug 12, 2024. It has published 4 rating actions on PCRX since July 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a PCRX price target in the last 12 months, the median target is $29.

Current rating
Underweight
Price target
$10
Median target, all firms
$29
Actions on PCRX
4

J.P. Morgan price target on PCRX

$83$47$1020222023202420252026
J.P. Morgan price target on PCRX, each point a stated target, July 2021 to August 2024.

Every J.P. Morgan rating on PCRX

How other firms rate PCRX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerOutperform$32Sep 23, 2026
Leerink PartnersMarket Perform$28Sep 9, 2026
Truist SecuritiesBuy$30Aug 17, 2026
BarclaysEqual Weight$27Dec 9, 2025
H.C. WainwrightBuyNov 17, 2025

Questions about J.P. Morgan and PCRX

What is J.P. Morgan's price target for PCRX?
J.P. Morgan's latest stated price target for Pacira BioSciences Inc. (PCRX) is $10, from its action on Aug 12, 2024.
What is J.P. Morgan's rating on PCRX?
J.P. Morgan rates PCRX Underweight, a bearish rating, as of Aug 12, 2024.
When did J.P. Morgan last change its view on PCRX?
On Aug 12, 2024, J.P. Morgan downgrades to Underweight from Overweight, price target $45 to $10.
How does J.P. Morgan's PCRX target compare with other analysts?
Across 4 firms with a PCRX price target in the last 12 months, the median target is $29.

More PCRX rating histories

All J.P. Morgan ratingsPCRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.